Guru Fundamental Report for ELV

Validea's guru fundamental report assigns Elevance Health (ELV), a large-cap health insurer, a 79% rating using the John Neff 'Low PE Investor' model, placing it just below the 80% threshold for 'some interest.' The stock demonstrates strong P/E, EPS growth, sales growth, and free cash flow, but failed criteria for total return/PE and EPS persistence, indicating a mixed fundamental profile within this value-oriented investment strategy.

Analysis

Elevance Health (ELV) presents a compelling but ultimately mixed profile based on Validea's quantitative screen using the John Neff 'Low PE Investor' model. The company received a score of 79%, positioning it just below the 80% threshold that typically signifies interest from this value-oriented strategy. ELV demonstrates robust fundamentals by passing key criteria for its P/E ratio, EPS growth, future EPS growth, sales growth, and free cash flow, indicating a profitable and growing business. However, two critical failures temper this positive view. The first, a 'FAIL' on the Total Return/PE metric, suggests that the stock's valuation may not be sufficiently discounted relative to its combined earnings growth and dividend yield. The second, and perhaps more significant for a Neff-style analysis, is the failure on 'EPS Persistence,' which points to a potential lack of consistency in historical earnings growth, a core tenet for the strategy. Therefore, while ELV is a fundamentally sound large-cap insurer, it does not fully align with the strict criteria of a deep value, persistent-growth investment approach.

Key Decisions for Investors

• Strict value investors following the Neff model should exercise caution, as the 79% score and failure on 'EPS Persistence' suggest ELV does not yet meet the criteria for a high-conviction holding.
• Investors with a 'Growth at a Reasonable Price' (GARP) focus might find ELV's profile attractive, given its positive ratings on P/E, sales growth, and future EPS growth.
• Monitor future quarterly earnings for evidence of improved earnings consistency, as a sustained trend could resolve the 'EPS Persistence' issue and make the stock more appealing to value strategies.
• The failure on the 'Total Return/PE' metric warrants further due diligence on the stock's valuation to confirm if the current price offers an adequate margin of safety relative to its growth and yield.